Leadership Change at Segmed: New CEO and Board Additions
Co-Founder Dr. Martin Willemink transitions to Chief Scientific Officer; Dr. Yin Ho joins the Board of Directors
Segmed, Inc., recognized for its innovative approach to real-world imaging data essential for research and AI development, has made significant leadership changes. The company has appointed David Gascoigne as its new Chief Executive Officer, marking an exciting chapter in its growth and innovation journey.
David Gascoigne's Vision for Segmed
Bringing over 30 years of experience, David Gascoigne stands at the forefront of Segmed's leadership transformation. His diverse background spans healthcare, life sciences, AI, and real-world data. Previously, he was the CEO of Almaden Genomics, where he spearheaded the rollout of a pioneering no-code genomics platform developed from IBM Research. This platform was groundbreaking in simplifying genomic data analysis, a crucial development for researchers and life science companies alike.
The Value of Real-World Data
David's expertise is invaluable as he shifts gears to lead Segmed into new market opportunities while striving to meet the evolving needs of the healthcare sector. His past roles at IQVIA and Symphony Health demonstrate a robust capability to convert complex real-world data into high-value solutions that enhance outcomes for healthcare organizations. His educational background includes an advanced degree in Applied Statistics from the University of Sheffield in the U.K., equipping him with the academic tools necessary for leading data-driven initiatives.
The Role of Dr. Martin Willemink
As Segmed embarks on its next phase, the previous CEO, Dr. Martin Willemink, will shift focus to his new role as Chief Scientific Officer. Dr. Willemink, a seasoned physician-scientist and epidemiologist, is well-known for his extensive work in cardiovascular imaging research, contributing to over 100 peer-reviewed publications. Under his guidance over the past three years, Segmed raised substantial funding and significantly expanded its global data partnerships.
Fostering Innovations in Healthcare
Dr. Willemink's leadership saw Segmed enhance its AI-ready data platform, establishing the company as a key player in the healthcare AI ecosystem. His focus now will be on scientific advancement and fostering academic collaborations to propel Segmed into its next growth phase.
Welcoming Dr. Yin Ho to the Board
In addition to the leadership changes, Segmed is excited to announce the appointment of Dr. Yin Ho, M.D., M.B.A. as an Independent Director. Dr. Ho brings rich experience from her extensive career in Healthcare IT and clinical research. Recently, she led Veradigm as interim CEO, advancing initiatives to improve electronic health record (EHR) data utilization in clinical research.
Her impressive background includes pivotal roles with pharmaceutical giants and innovative healthcare technology firms where she shaped IT ecosystems. With an M.D. from Yale and an M.B.A. from Harvard Business School, Dr. Ho’s strategic insights will be instrumental in enhancing Segmed's mission in accessible medical imaging data.
Commitment to Patient-Centered Innovation
Dr. Ho emphasizes the importance of patient-centered innovation, aligning perfectly with Segmed’s vision. Her experience will contribute to developing smarter healthcare solutions using high-quality medical imaging data. This commitment to innovation is echoed by both CEO David Gascoigne and Dr. Willemink, who recognize the necessity of evolving with the rapidly changing healthcare landscape.
Future Directions for Segmed
With these leadership transitions, Segmed is poised to deepen its operational excellence and enhance its scientific leadership. The company’s transformation aligns with its goals to expedite platform expansions and collaborate more intensively in research, paving the way for innovations at the intersection of healthcare and AI.
Founded in 2019, Segmed has focused on providing diagnostic-grade medical images to advance biopharmaceutical R&D and healthcare initiatives efficiently. As it embraces this new chapter, Segmed remains committed to eliminating the lengthy processes traditionally associated with acquiring imaging data, ensuring researchers and developers can access what they need promptly.
About Segmed
Segmed, Inc. collaborates with life sciences and healthcare technology firms, enhancing R&D access to medical imaging. The company improves how researchers utilize medical imaging data, making it accessible, actionable, and transformative for innovative applications. Their work exemplifies a commitment to advancing the science behind healthcare solutions.
Frequently Asked Questions
What leadership changes have occurred at Segmed?
David Gascoigne has been appointed CEO, with Dr. Martin Willemink becoming Chief Scientific Officer and Dr. Yin Ho joining the Board of Directors.
What experience does David Gascoigne bring to Segmed?
David has over 30 years of industry experience and previously led Almaden Genomics, focusing on innovative, no-code data solutions.
What role will Dr. Martin Willemink have moving forward?
Dr. Willemink will focus on scientific advancements and collaborations as Segmed's Chief Scientific Officer.
How does Segmed plan to address healthcare innovation?
Segmed aims to expedite platform expansions and deepen research partnerships to drive innovations in the healthcare sector.
What is Segmed's mission?
The company aims to accelerate innovation in healthcare by providing accessible diagnostic-grade medical imaging data for research and AI development.
